Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib discontinuation in pediatric CML with sustained complete molecular response
2011-006239-44Phase 2Terminated
- Sponsor
- Dutch Childhood Oncology Group
- Start
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of imatinib in chronic myelogenous leukemia (CML), sponsored by Dutch Childhood Oncology Group. Started Oct 2012; status: terminated.
02
Drugs
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2011-006239-44.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-006239-44.